DrugPatentWatch Alpha Signals Regulatory Exclusivity

Accurate, objective, and timely intelligence

Regulatory Exclusivity: Orphan Drug

« Back to Dashboard

Drugs with Orphan Drug Regulatory Exclusivity

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Exclusivity Expiration	Patented / Exclusive Use
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-002	Nov 22, 2022		RX	Yes	No		FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-001	Mar 6, 2015		RX	Yes	Yes		TREATMENT OF INVASIVE ASPERGILLOSIS
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-001	Mar 6, 2015		RX	Yes	Yes		TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER

Regulatory Exclusivity

Search by exclusivity type:

Competitive Generic Therapy
New Chemical Entity
New Dosing Schedule
New Indication
New Product
New Patient Population
New Strength
Orphan Drug
Patent Challenge
Pediatric Exclusivity
RX to OTC Switch

Upgrade for More Features

Upgrade to a full subscription to unlock our entire dataset and to enjoy subscriber-only features.

Whether you need access for yourself or for your whole team, DrugPatentWatch offers subscription plans tailored to your needs. Attractive pricing is available for small groups or for enterprise-wide access.